- Research Grants
graduate at Química Industrial from Universidade Federal de Santa Maria (1993), master's at Chemistry from Universidade Federal de Santa Catarina (1996) and ph.d. at Química Orgânica from Universidade Federal de Santa Catarina (1999). Has experience in Chemistry, acting on the following subjects: química medicinal, inibidores enzimáticos, relações entre a estrutura e a atividade (sar) and qsar. (Source: Lattes Curriculum)
|News published in Agência FAPESP Newsletter about the researcher|
|International collaboration expands Brazilian biodiversitys natural product database|
|Consortium vows to find new drugs against Chagas disease, leishmaniosis and malaria|
|FAPESP e Karolinska Institutet querem ampliar parceria para inovação em saúde|
|Neglected diseases continue to require attention despite progress|
|Brazilian database of natural products receives international recognition|
The lack of robustly validated drug targets has proved a significant barrier to the discovery of new treatments for visceral leishmaniasis and Chagas' disease. Furthermore, target deconvolution studies with active leads emerging from current small molecule phenotypic screening have confirmed that the same relatively few molecular targets are being hit repeatedly. This project aims to ...
The Center for Innovation in Biodiversity and Drug Discovery (CIBFar) is a joint initiative resulting from existing collaborative research projects, including the Physics Institute of São Carlos (IFSC) and the School of Pharmaceutical Sciences of Ribeirão Preto at the University of São Paulo (USP), the Institute of Chemistry at the State University of São Paulo (UNESP), the Institute of...
An International Cooperative Biodiversity Group (ICBG) with an interdisciplinary leadership team of physicians, pharmacologists, evolutionary biologists, and chemists will discover and develop therapeutic agents produced by Brazilian symbiotic bacteria. The team will target three therapeutic areas: 1) infectious fungal pathogens, 2) Chagas disease and leishmaniasis, and 3), cancers of t...
Cancer consists of a group of diseases characterized by the disordered growth of abnormal cells capable of invading numerous tissues and organs. The World Health Organization (WHO) considers it to be the second leading cause of death worldwide, being responsible for almost 10 million of deaths in 2018. Although chemotherapy relies on an important arsenal of drugs, treatments are associa...
Biodiversity provides exclusive chemical scaffolds for the design of active compounds and is the main source of drugs approved worldwide (67% are either a natural product, semi-synthetic derivative, macromolecule isolated from an organism or have a pharmacophore group inspired by natural products). Natural products are efficient models for medicinal chemistry because they comprise scaff...
(Only some records are available in English at this moment)
Chagas disease is a neglected tropical disease that affects millions of people worldwide, mainly in Latin America, where it is endemic. According to the World Health Organization, Chagas disease is a high priority condition for the development of novel therapies. The available drugs are obsolete, and have low efficacy and outstanding toxicity. In this context, the discovery of novel tre...
Chagas' disease, also known as American trypanosomiasis, affects millions of people worldwide, mostly in Latin America, and is considered one of the neglected tropical diseases (NTD) of highest priority in the "Lead Discovery for Drugs for Tropical Infectious Diseases" program of the World Health Organization (WHO). The available drugs to fight the disease are extremely limited and have...
(Only some records are available in English at this moment)
Cruzain (EC 126.96.36.199) is the major cysteine protease from Trypanosoma cruzi, the Chagas disease etiological agent. Due to its biological relevance, this enzyme is considered one of the most relevant targets to develop new anti-chagasics, which is urgent once the available therapy is old and very toxic due to a blend of unsatisfactory side effects and lack of efficacy. In this way, the ...
Cancer is the name of a group of devastating diseases characterized by uncontrolled growth and multiplication of abnormal cells capable of invading nearby structures and spread in various regions of the body. These malignant cells fail to respond to control and defense mechanisms of the body, continually doubling in a disorderly manner and causing tumors. The world scenario caused by de...
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
|Data from Web of Science|
(References retrieved automatically from State of São Paulo Research Institutions)
SANTOS, Ricardo Nascimento dos. Planejamento de moduladores de polimerização de microtúbulos com propriedades anticâncer, análise estrutural de macromoléculas e geração de uma base virtual de produtos naturais. Tese (Doutorado) - Instituto de Física de São Carlos. Universidade de São Paulo (USP). São Carlos. (10/06741-4)
MODA, Tiago Luiz. Modelagem In silico de propriedades farmacocinéticas para a avaliação de candidatos a novos fármacos. Tese (Doutorado) - Instituto de Física de São Carlos. Universidade de São Paulo (USP). São Carlos. (07/00440-0)
SALUM, Lívia de Barros. Planejamento de ligantes da tubulina com propriedades antitumorais. Tese (Doutorado) - Instituto de Física de São Carlos. Universidade de São Paulo (USP). São Carlos. (07/07294-9)
FERREIRA, Leonardo Luiz Gomes. Identificação de novos inibidores da enzima aldolase de Trypanosoma brucei. Tese (Doutorado) - Instituto de Física de São Carlos. Universidade de São Paulo (USP). São Carlos. (08/10727-7)
ALTEI, Wanessa Fernanda. Triagem biológica, identificação e planejamento de novos candidatos a agentes anticâncer a partir de produtos naturais e compostos sintéticos. Tese (Doutorado) - Instituto de Física de São Carlos. Universidade de São Paulo (USP). São Carlos. (09/15320-5)
PAULI, Ivaní. Planejamento de inibidores da enzima cruzaína candidatos a fármacos para o tratamento da doença de Chagas. Tese (Doutorado) - Instituto de Física de São Carlos. Universidade de São Paulo (USP). São Carlos. (11/13789-6)